RxSight (RXST) Income from Non-Controlling Interests (2020 - 2024)
RxSight's (RXST) quarterly Income from Non-Controlling Interests came in at $155000.0 in Q4 2024, up 89.02% on a YoY basis from $82000.0 in Q1 2024, and up 3000.0% quarter-over-quarter from $5000.0 in Q3 2024.
Powered by 
Analysis
RxSight (RXST) Income from Non-Controlling Interests (2020 - 2024) Analysis & Trends
RxSight (RXST) has reported Income from Non-Controlling Interests for 5 consecutive years, with $155000.0 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Income from Non-Controlling Interests rose 89.02% year-over-year to $155000.0; the trailing twelve-month figure through Dec 2024 stood at $170000.0 (up 88.89% YoY), and the FY2025 full-year result was $1.7 million, up 876.02% from the prior year.
- Income from Non-Controlling Interests rose to $155000.0 in Q4 2024 per RXST's latest filing, from $5000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.6 million in Q4 2022 and bottomed at $1000.0 in Q2 2021.
- Historically, Income from Non-Controlling Interests has averaged $99947.4 across 5 years, with a median of $4000.0 in 2020.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests soared 161200.0% in 2022, then tumbled 94.92% in 2023.
- Over 5 years, Income from Non-Controlling Interests stood at $2000.0 in 2020, then plunged by 50.0% to $1000.0 in 2021, then jumped by 161200.0% to $1.6 million in 2022, then sank by 94.92% to $82000.0 in 2023, then surged by 89.02% to $155000.0 in 2024.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $155000.0, $5000.0, and $5000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 6.60 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 9.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -2.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -500,000.00 |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | - |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 900,000.00 |
| 10 | RxSight | 265.13 Mn | -139.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 1.61 Mn |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 4,000.00 |